Date Name Title Type Shares Traded Price
Dec 14, 2012
SVP Res and Devel Sciences
SVP Res and Devel Sciences Grant, award or other acquisition pursuant to Rule 16b-3(d) 112,500 --
Jan 05, 2005
SVP, PreclinDevel & Biomol Sci
SVP, PreclinDevel & Biomol Sci Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 100,000 --
Dec 17, 2007
SVP, Research & Devel Sciences
SVP, Research & Devel Sciences Grant, award or other acquisition pursuant to Rule 16b-3(d) 95,438 --
Jun 18, 2012
SVP Res & Dev Sciences
SVP Res & Dev Sciences Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 95,079 $20.32
Jun 18, 2012
SVP Res & Dev Sciences
SVP Res & Dev Sciences Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 95,079 --
Dec 18, 2006
SVP, Therap & Clin Prog Dev
SVP, Therap & Clin Prog Dev Grant, award or other acquisition pursuant to Rule 16b-3(d) 95,079 --
Aug 04, 2022
EVP Research and Development
EVP Research and Development Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 95,000 $270.43
Aug 04, 2022
EVP Research and Development
EVP Research and Development Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 95,000 --
Dec 13, 2013
SVP Research and Development S
SVP Research and Development S Grant, award or other acquisition pursuant to Rule 16b-3(d) 95,000 --
Jan 05, 2005
SVP, PreclinDevel & Biomol Sci
SVP, PreclinDevel & Biomol Sci Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 94,851 --

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.